Inhibikase Therapeutics, Inc. (NYSE:IKT - Get Free Report) Director Arvind Kush acquired 145,000 shares of Inhibikase Therapeutics stock in a transaction on Monday, October 21st. The shares were bought at an average cost of $1.37 per share, for a total transaction of $198,650.00. Following the completion of the purchase, the director now directly owns 145,000 shares of the company's stock, valued at $198,650. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Inhibikase Therapeutics Trading Up 15.2 %
Inhibikase Therapeutics stock opened at $2.43 on Thursday. The firm has a market capitalization of $17.53 million, a PE ratio of -0.73 and a beta of 1.32. Inhibikase Therapeutics, Inc. has a 12-month low of $0.80 and a 12-month high of $3.82. The firm has a 50-day moving average price of $1.39 and a 200-day moving average price of $1.51.
Inhibikase Therapeutics (NYSE:IKT - Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.08). As a group, sell-side analysts predict that Inhibikase Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.
Analyst Ratings Changes
Blackrock’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media | Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains.
The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW
Separately, HC Wainwright cut their target price on Inhibikase Therapeutics from $15.00 to $5.00 and set a "buy" rating on the stock in a research report on Monday, October 14th.
View Our Latest Stock Report on IKT
Institutional Trading of Inhibikase Therapeutics
An institutional investor recently bought a new position in Inhibikase Therapeutics stock. Armistice Capital LLC bought a new position in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 589,575 shares of the company's stock, valued at approximately $713,000. Armistice Capital LLC owned 8.17% of Inhibikase Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 3.81% of the company's stock.
About Inhibikase Therapeutics
(
Get Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
